Herman Overkleeft
Overview
Explore the profile of Herman Overkleeft including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
319
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Paone P, Latousakis D, Terrasi R, Vertommen D, Jian C, Borlandelli V, et al.
Gut
. 2024 May;
73(10):1632-1649.
PMID: 38740509
Objective: To decipher the mechanisms by which the major human milk oligosaccharide (HMO), 2'-fucosyllactose (2'FL), can affect body weight and fat mass gain on high-fat diet (HFD) feeding in mice....
2.
Vocadlo D, Overkleeft H
Curr Opin Chem Biol
. 2019 Dec;
53:A1-A3.
PMID: 31864526
No abstract available.
3.
Herrera Moro Chao D, Wang Y, Foppen E, Ottenhoff R, van Roomen C, Parlevliet E, et al.
Diabetes
. 2019 Oct;
68(12):2223-2234.
PMID: 31578192
Obesity is taking on worldwide epidemic proportions, yet effective pharmacological agents with long-term efficacy remain unavailable. Previously, we designed the iminosugar N-adamantine-methyloxypentyl-deoxynojirimycin (AMP-DNM), which potently improves glucose homeostasis by lowering...
4.
Moiola M, Crespi S, Memeo M, Collina S, Overkleeft H, Florea B, et al.
ACS Omega
. 2019 Aug;
4(4):7766-7774.
PMID: 31459866
Anthracenenitrile oxide undergoes 1,3-dipolar cycloaddition reactions with 1-substituted-4-(prop-2-yn-1-yloxy)benzene affording the expected isoxazoles in good yields and as single regioisomers. N-O Bond cleavage and boron complexation afforded the corresponding boron complexes,...
5.
Kraus J, Kraus M, Liu N, Besse L, Bader J, Geurink P, et al.
Cancer Chemother Pharmacol
. 2015 Jun;
76(2):383-96.
PMID: 26099967
Purpose: Proteasome-inhibiting drugs (PI) are gaining importance in hematologic oncology. The proteasome carries three proteolytically active subunits (β1, β2, β5). All established PI (bortezomib and carfilzomib), as well as experimental...
6.
Kraus M, Bader J, Geurink P, Weyburne E, Mirabella A, Silzle T, et al.
Haematologica
. 2015 Jun;
100(10):1350-60.
PMID: 26069288
Proteasome inhibitor resistance is a challenge for myeloma therapy. Bortezomib targets the β5 and β1 activity, but not the β2 activity of the proteasome. Bortezomib-resistant myeloma cells down-regulate the activation...
7.
Kraus M, Muller-Ide H, Ruckrich T, Bader J, Overkleeft H, Driessen C
Leuk Res
. 2014 Jan;
38(3):383-92.
PMID: 24418752
Background: Protein metabolism is an innovative potential therapeutic target for AML. Proteotoxic stress (PS) sensitizes malignant cells for proteasome inhibitor treatment. Some HIV protease inhibitors (HIV-PI) induce PS and may...
8.
Yu H, Segers F, Sliedregt-Bol K, Bot I, Woltman A, Boross P, et al.
FASEB J
. 2013 Jul;
27(10):4136-46.
PMID: 23896727
The CD40/CD40L dyad is deemed to play a central role in several inflammatory processes, including atherosclerosis. As CD40 is overexpressed in atherosclerotic lesions, it constitutes a promising candidate for targeted...
9.
10.
Yu H, Bot I, Sliedregt K, Xu X, Bot M, van Heiningen S, et al.
Circ Res
. 2011 Nov;
110(2):200-10.
PMID: 22116820
Rationale: Nuclear factor of activated T-cells (NFAT) is importantly implicated in pathological cardiac remodeling and vascular lesion formation. NFAT functionality is mainly regulated by calcineurin, a Ca(2+)-dependent multi-effector phosphatase. Calcineurin...